Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Megan Leary

Neurology Allentown, PA Medical Doctor

NPI 1669419859 CMS profile 75375

1250 S Cedar Crest Blvd, Suite 405, Allentown, PA 18103

Open in the dashboard

General payments

$47,998

63 records reported · program years 2019–2025

Research payments

$20,498

Paid to them · 21 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$190,748 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Megan Leary of Allentown, PA is reported in the CMS Open Payments database as having received $47,998 across 63 general payments and $20,498 in research payments paid to them. Separately, studies naming them as principal investigator received $190,748 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,375 17
2024 General $9,110 12
2024 Research $10,400 4
2023 General $1,615 3
2023 Research $8,833 4
2022 General $9,000 10
2021 General $1,301 2
2020 General $3,805 9
2019 General $6,792 10
2019 Research $1,265 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Megan Leary
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Megan Leary were reported at $16,375. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Megan Leary Neurology median Middle half National median
2019 $6,792 $474 $118–$2,177 $163
2020 $3,805 $367 $82–$2,309 $114
2021 $1,301 $438 $104–$2,547 $132
2022 $9,000 $442 $103–$2,388 $149
2023 $1,615 $464 $119–$2,312 $160
2024 $9,110 $468 $119–$2,323 $164
2025 $16,375 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $20,066 27 payments
  2. Boston Scientific Corporation $11,860 13 payments
  3. Abbott Laboratories $7,998 15 payments
  4. Beckman Coulter, Inc. $3,500 1 payment
  5. CSL Behring $2,755 4 payments
  6. CryoLife, Inc. $1,800 2 payments
  7. Stryker Corporation $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $47,979 62 payments
  2. Food and Beverage $19 1 payment
Products named General payments · program years 2019–2025
  1. CLINICAL TRIAL PRODUCT $8,410 10 payments
  2. DXI 9000 Access Immunoassay Analyzer $3,500 1 payment
  3. Synergy $3,450 3 payments
  4. Absorb GT1 $2,488 4 payments
  5. Tendyne Mitral Valve System $2,325 6 payments
  6. AMDS-Ascyrus Medical $1,800 2 payments
  7. Mitra Clip system $50 1 payment
  8. TREVO $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. CryoLife, Inc. $19,233 8 payments
  2. Novo Nordisk AS $1,265 13 payments

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$22,592

Medicare's payments for the services billed

Medicare patients

184

Average age 77

Services billed

258

96 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Chronic kidney disease 55%
Diabetes 53%
Ischemic heart disease 47%
Heart failure 43%
Atrial fibrillation 43%
Depression 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record